Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of Cybin (NYSEAM:CYBN) with a Buy recommendation.

Mintz’s Los Angeles Real Estate Group as a member in October 2020. He was previously a partner in the Real Estate Group at ...

A Manhattan art dealer who claims to be related to a famed family allegedly left his Swiss wedding planner on the hook for ...

DICK’S Sporting Goods (NYSE:DKS – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports.

Immersive AI Art installation created by Turkish Artist Refik Anadol pays homage to Architect Frank Gehry in inaugural 'in ...

Guggenheim initiated coverage of Cybin (CYBN) with a Buy rating and $35 price target Light Up your Portfolio with Spark:Easily identify stocks' ...

One reason Tesla investors should sell into the stock’s recent bounce is because of all the “political noise” surrounding ...

Art dealer Gordon VeneKlasen abhors censorship but concedes that China represents a huge, still untapped market: “Asia is a ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 ...